BETHESDA, Md.--(BUSINESS WIRE)--The use of adiponectin, a hormone derived from fat cells, was confirmed as a robust biomarker predictive of glycemic efficacy in Type 2 diabetes and healthy subjects, after treatment with peroxisome proliferator-activated receptor-agonists (PPAR), but not after treatment with non-PPAR drugs such as metformin. The findings were the result of the first project completed by the Biomarkers Consortium, a public-private partnership managed by the Foundation for the National Institutes of Health. The project conducted a statistical analysis of pooled and blinded pre-existing data from Phase II clinical trials contributed by four pharmaceutical companies and analyzed under the direction of a diverse team of scientists from industry, the National Institutes of Health (NIH), U.S. Food & Drug Administration (FDA), and academic research institutions.
